Therapix Biosciences Ltd. (TRPX)’s Financial Results Comparing With Catalyst Biosciences Inc. (NASDAQ:CBIO)

Therapix Biosciences Ltd. (NASDAQ:TRPX) and Catalyst Biosciences Inc. (NASDAQ:CBIO), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Therapix Biosciences Ltd. 2 0.00 4.02M -2.57 0.00
Catalyst Biosciences Inc. 5 0.05 7.15M -3.36 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Therapix Biosciences Ltd. 196,971,924.15% 0% 0%
Catalyst Biosciences Inc. 130,952,380.95% -32.6% -31.5%

Insider & Institutional Ownership

Therapix Biosciences Ltd. and Catalyst Biosciences Inc. has shares owned by institutional investors as follows: 0% and 82.9%. About 2.08% of Therapix Biosciences Ltd.’s share are owned by insiders. On the other hand, insiders owned about 0.4% of Catalyst Biosciences Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Therapix Biosciences Ltd. -12.16% 4.84% -24.2% -28.77% -30.48% -20%
Catalyst Biosciences Inc. -1.92% 10.38% -5.43% -4.21% -15.39% 3.8%

For the past year Therapix Biosciences Ltd. had bearish trend while Catalyst Biosciences Inc. had bullish trend.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.